Pharminent

Celltrion sets sights on 2017 for EU and US rituximab biosimilar success

Celltrion is confident that 2017 will bring European approval and a US filing for Truxima, after achieving regulatory success for the Rituxan biosimilar in Korea. http://www.biopharma-reporter.com/Markets-Regulations/Celltrion-sets-sights-on-2017-for-EU-US-Rituxan-biosimilar-success

Filed under: Biosimilar